Real-World Joint Outcomes After Selective Transition to Low-Dose Emicizumab in Pediatric Hemophilia A

NCT07439055 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

18

Enrollment

OTHER

Sponsor class

Conditions

Hemophilia A Patient

Interventions

DRUG: Switching to low dose emicizumab

Sponsor

Chulalongkorn University